The Latin America, Middle East and Africa Drug Eluting Stent Market would witness market growth of 12.5% CAGR during the forecast period (2023-2030). In the year 2026, the LAMEA market's volume is expected to surge to 1,036.9 thousand units, showcasing a growth of 15.0% (2023-2030).
The first-generation devices' performance was severely constrained by polymer-related adverse effects, which significantly decreased by the introduction of new, more biocompatible, robust polymers, and biodegradable polymers in the new-generation DES. Additionally, the persistent restriction of excessive neointimal proliferation and the improved administration of antiproliferative drugs considerably decreased restenosis rates. The current-generation DES's reduced rates of restenosis, recurrent myocardial infarction, and stent thrombosis are not a result of any single component but rather the overall device's design.
Furthermore, it is essential that interventional cardiologists fully comprehend the design elements of the various devices because the stent design is vital for both short-term and long-term cardiovascular outcomes. Stenting is now much simpler to integrate into the interventional environment owing to quick developments in stent designs and delivery technologies, reducing the incidence of restenosis, even for the most challenging lesions. However, in response to the emergence of stent thrombosis, market participants in the market are focusing on developing a newer generation of drug eluting stents that assist in eradicating this catastrophic consequence.
According to the Saudi Arabia government, over 30% of Saudi Arabia's adult population (18 years and older) is at risk of developing CVD. In Saudi Arabia, CVD is linked to smoking, eating a diet heavy in fat and poor fiber, and leading a sedentary lifestyle. Numerous individuals also have several additional comorbid diseases or hazards, including diabetes mellitus (12.3%), smoking (16%), hypertension (22%), and high cholesterol or dyslipidemia (35–40%). Thirty-five percent of the country's population has cholesterol levels above the advised target, according to numerous national and international multicentric research. All these factors will help boost the demand in the LAMEA region.
The Brazil market dominated the LAMEA Drug Eluting Stent Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $288.7 million by 2030. The Argentina market is showcasing a CAGR of 13.1% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 12.2% during (2023 - 2030).
Based on Application, the market is segmented into Coronary Artery Disease, and Peripheral Artery Disease. Based on Coating Type, the market is segmented into Polymer-based Coating (Non-biodegradable Polymers, and Biodegradable Polymers), and Polymer-free Coating (Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface). Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.), Cook Medical, Inc. (Cook Group), B. Braun Melsungen AG, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd and Alvimedica.
The first-generation devices' performance was severely constrained by polymer-related adverse effects, which significantly decreased by the introduction of new, more biocompatible, robust polymers, and biodegradable polymers in the new-generation DES. Additionally, the persistent restriction of excessive neointimal proliferation and the improved administration of antiproliferative drugs considerably decreased restenosis rates. The current-generation DES's reduced rates of restenosis, recurrent myocardial infarction, and stent thrombosis are not a result of any single component but rather the overall device's design.
Furthermore, it is essential that interventional cardiologists fully comprehend the design elements of the various devices because the stent design is vital for both short-term and long-term cardiovascular outcomes. Stenting is now much simpler to integrate into the interventional environment owing to quick developments in stent designs and delivery technologies, reducing the incidence of restenosis, even for the most challenging lesions. However, in response to the emergence of stent thrombosis, market participants in the market are focusing on developing a newer generation of drug eluting stents that assist in eradicating this catastrophic consequence.
According to the Saudi Arabia government, over 30% of Saudi Arabia's adult population (18 years and older) is at risk of developing CVD. In Saudi Arabia, CVD is linked to smoking, eating a diet heavy in fat and poor fiber, and leading a sedentary lifestyle. Numerous individuals also have several additional comorbid diseases or hazards, including diabetes mellitus (12.3%), smoking (16%), hypertension (22%), and high cholesterol or dyslipidemia (35–40%). Thirty-five percent of the country's population has cholesterol levels above the advised target, according to numerous national and international multicentric research. All these factors will help boost the demand in the LAMEA region.
The Brazil market dominated the LAMEA Drug Eluting Stent Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $288.7 million by 2030. The Argentina market is showcasing a CAGR of 13.1% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 12.2% during (2023 - 2030).
Based on Application, the market is segmented into Coronary Artery Disease, and Peripheral Artery Disease. Based on Coating Type, the market is segmented into Polymer-based Coating (Non-biodegradable Polymers, and Biodegradable Polymers), and Polymer-free Coating (Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface). Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.), Cook Medical, Inc. (Cook Group), B. Braun Melsungen AG, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd and Alvimedica.
Scope of the Study
Market Segments Covered in the Report:
By Application (Volume, Thousand Units, USD Million, 2019-2030)- Coronary Artery Disease
- Peripheral Artery Disease
- Polymer-based Coating
- Non-biodegradable Polymers
- Biodegradable Polymers
- Polymer-free Coating
- Micro Porous Surface
- Micro Structured Surface
- Slotted Tubular Surface
- Nanoporous Surface
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic PLC
- Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.)
- Cook Medical, Inc. (Cook Group)
- B. Braun Melsungen AG
- Biotronik SE & Co. KG
- Lepu Medical Technology Co., Ltd
- Alvimedica
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Drug Eluting Stent Market by Application
Chapter 5. LAMEA Drug Eluting Stent Market by Coating Type
Chapter 6. LAMEA Drug Eluting Stent Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic PLC
- Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.)
- Cook Medical, Inc. (Cook Group)
- B. Braun Melsungen AG
- Biotronik SE & Co. KG
- Lepu Medical Technology Co., Ltd
- Alvimedica
Methodology
LOADING...
